Gonorrhea Therapeutics Market Revenue Predicted to Go Up by 2029
As per this Fact.MR report, there has been an evident surge in the prevalence of gonorrhea which is resistant to components of dual antibiotic therapy – azithromycin and ceftriaxone, known to be the only suggested treatment for gonorrhea. With a swing of hopeful new antibiotics together with education, surveillance and preventative measures to impasse prevalence of super-resistant gonorrhea, the prospects seem optimistic for the gonorrhea therapeutics market. In order to acquire better insight into the gonorrhea therapeutics market, Fact.MR has...
View full press release